oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 359 )

2018 ( 1278 )

2017 ( 1321 )

2016 ( 1513 )

Custom range...

Search Results: 1 - 10 of 382166 matches for " S.Yu. Martsevich "
All listed articles are free for downloading (OA Articles)
Page 1 /382166
Display every page Item
The congress of the European Society of Cardiology 2010 in Stockholm: news for practitioners
S.Yu. Martsevich
Rational Pharmacotherapy in Cardiology , 2010,
Abstract: News about Congress of the European Society of Cardiology 2010 in Stockholm is presented. The main significant events of the Congress are discussed. Symposia on antiplatelet therapy, hypertension, and recently completed research results are highlighted.
The use of angiotensin converting enzyme inhibitors after myocardial infarction. What do evidence-based medicine data speak for?
S.Yu. Martsevich
Rational Pharmacotherapy in Cardiology , 2010,
Abstract: The main trails proven angiotensin converting enzyme (ACE) inhibitor effects on the life prognosis after myocardial infarction (MI) are described. Different tactics of ACE inhibitors therapy in post MI patients are presented. Approaches to the choice of a specific ACE inhibitor are discussed.
Congress of European Society of Cardiology in Paris: what practical physician should take for the notes
S.Yu. Martsevich
Rational Pharmacotherapy in Cardiology , 2011,
Abstract: The main events of the Congress of the European Society of Cardiology (ESC) held in Paris, (August 27-31, 2011) are highlighted. The results of recently completed randomized controlled studies, pharmacoepidemiological studies, additional analysis of a number of previously completed studies, new clinical ESC guidelines, as well as results of debates on controversial issues in cardiology, assessment of clinical trials data and therapy compliance are presented.
New antiarrhythmic drug for the treatment of atrial fibrillation. Study data, clinical guidelines, regulatory agency recommendations
S.Yu. Martsevich,Yu.V. Lukina
Rational Pharmacotherapy in Cardiology , 2011,
Abstract: he main objectives and strategies for treatment of atrial fibrillation (AF), one of the most common cardiac arrhythmia, are seen. A combination of strategies for heart rate control in patients with atrial fibrillation receiving rhythm-controling therapy is preferred at present, according to current guidelines. Amiodarone, one of the most effective anti-arrhythmic drugs with an extensive evidence base, remains the drug of reserve because of serious side effects. A new drug, dronedarone, has electrophysiological properties attributable to all four classes of antiarrhythmic drugs. According to meta-analysis of randomized clinical trials dronedarone is inferior to amiodarone in prevention of AF recurrences, but it is superior to amiodaron in safety. However, in 2011 dronedarone was included in the Food and Drug Administration (FDA) list of drugs that require further analysis in connection with appearance of the new information about its safety.
Positions of calcium channel blocker lercanidipine according to evidence based cardiology
Yu.V. Lukina,S.Yu. Martsevich
Rational Pharmacotherapy in Cardiology , 2010,
Abstract: Data of evidence based cardiology including results of international clinical trials on efficacy and safety of the modern calcium channel blocker (CCB), lercanidipine, are presented. Results of these trials show the firm position of lercanidipine in the modern cardiology and confirm that treatment with lercanidipine leads to significant reduction of systolic and diastolic blood pressure (BP) with no effect on heart rate (HR). Peripheral edema (the common side effect of CCBs) occurs rarer with lercanidipine treatment than this with any other CCB treatment. Lercanidipine can be recommended to patients with concomitant diseases due to its additional features.
Combination therapy of hypertension — a reliable way to target achieve
Yu.V. Lukina,S.Yu. Martsevich
Rational Pharmacotherapy in Cardiology , 2010,
Abstract: Data of evidence-based cardiology and clinical guidelines that define the position of combined therapy to achieve the targets of hypertension (HT) treatment (achievement and maintenance of the target blood pressure (BP) level, protection of the target organs, improvement of the quality of life in hypertensive patients) are presented in the article. The advantages of rational combined therapies (potentiation of antihypertensive effect, reduction of a number of adverse events) are considered. Studies of therapeutic efficacy and safety of combined antihypertensive therapy based on generics are important. The advantages of combined therapy in achievement of target BP levels are presented on example of comparative study of new generic and original amlodipine in patients with HT of 1-2 degrees. Target BP level was reached respectively in 90% and 97% of patients with HT in groups of generic and original amlodipine combined with generic lisinopril and hydrochlorothiazide. Safety profile was acceptable. This confirms the high efficacy of amlodipine + lisinopril + hydrochlorothiazide combination, including one on the basis of generics.
The bisoprolol — a high selective beta-blocker according to evidence based medicine
Yu.V.Lukina,S.Yu.Martsevich
Rational Pharmacotherapy in Cardiology , 2010,
Abstract: Data of the evidence based medicine about bisoprolol treatment of patients with cardiovascular diseases (arterial hypertension, ischemic heart disease, chronic heart failure, rhythm disorders) are presented. Implementation of bisoprolol generics as well as bisoprolol usage in smoking cardiovascular patients is also discussed.
Problem of generic replacement: advantages and disadvantages
S.N. Tolpygina,S.Yu. Martsevich
Rational Pharmacotherapy in Cardiology , 2009,
Abstract: The main differences between original and generic drugs as well as registration criteria for generics are described. Possible reasons of discrepancy in bioequivalence and therapeutic equivalence of original and generic drugs are reviewed. The examples of such a discrepancy as a result of comparative clinical trails (enalapril maleate) are discussed. Approaches to planning of comparative trails on drug therapeutic equivalence are presented.
The STICH trial — the importance of drugs in patients with coronary artery disease was higher than expected
S.Yu. Martsevich,N.P. Kutishenko
Rational Pharmacotherapy in Cardiology , 2011,
Abstract: Key findings of STICH (Surgical Treatment for Ischemic Heart Failure) trial are presented. This study goal was to evaluate the role of the surgical intervention for coronary artery bypass grafting in improvement of life prognosis in patients with ischemic heart disease complicated severe heart failure.
Evaluation by practicing doctors of the modern pharmacotherapy possibilities in patients with ischemic heart disease. Results of doctor interview in Moscow and Voronezh
S.Yu. Martsevich,L.Yu. Drozdova,Yu.V. Lukina,N.V. Sinyagina
Rational Pharmacotherapy in Cardiology , 2010,
Abstract: Aim. To evaluate opinion of doctors about modern pharmacotherapy possibilities in patients with ischemic heart disease (IHD) and about basic problems of pharmacotherapy implementation.Material and methods. Interviews of doctors from various health care institutions in Moscow and Voronezh were performed in 2009. Interview was performed with questionnaire containing 5 questions. Doctors of different specialties (n=64 from Moscow and n=69 from Voronezh) participated in interviewing.Results. The majority of doctors in Moscow and Voronezh were sure in advantage of IHD pharmacotherapy vs coronary angioplasty and stenting (55% and 63%, respectively). Only 37% and 32% of doctors in Moscow and Voronezh, respectively, believed in real achievement of target levels of low density cholesterol and 45% and 61% of them, respectively, considered high cost of statins as the main limit for its implementation.Conclusion. On one hand interviews among practicing doctors in Moscow and Voronezh demonstrated satisfied knowledge of modern clinical guidelines on IHD therapy. On the other hand they gave understanding why doctors not always follow these guidelines.
Page 1 /382166
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.